Tomuzotuximab

{
  "id": "MLC-T-ONC-017235",
  "term": "Tomuzotuximab",
  "field": "Oncology and biomedicine",
  "definition": "A glycoengineered second-generation antibody of cetuximab with potential antineoplastic activities. Upon intravenous administration, tomuzotuximab selectively binds to the extracellular domain of the epidermal growth factor receptor (EGFR), thereby preventing the activation and subsequent dimerization of the receptor. This may prevent EGFR-mediated signaling and inhibit EGFR-dependent tumor cell proliferation. Further, tomuzotuximab has a fully human glycosylation pattern and is glyco-optimized at its Fc domain to promote antibody-dependent cell-mediated cytotoxicity (ADCC). EGFR, a member of the epidermal growth factor family of extracellular protein ligands, may be overexpressed on the cell surfaces of certain tumor types.",
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/tomuzotuximab/"
}